Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst

Loading...Loading...Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.RBC Capital Markets anticipates a favorable second-quarter environment for companies outside of China. They expect the third quarter to follow typical seasonal patterns without backlog issues, with robust MedTech markets projected for 2024 and beyond.Johnson & Johnson maintains its consistent M&A strategy, affirming continuity even after acquiring Shockwave Medic ...